KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cash & Equivalents: 2009-2025

Historic Revenue - Interest and Investment Income for Jazz Pharmaceuticals (JAZZ) over the last 2 years, with Mar 2011 value amounting to $154.2 million.

  • Jazz Pharmaceuticals' Cash & Equivalents fell 40.22% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 40.22%. This contributed to the annual value of $2.4 billion for FY2024, which is 60.18% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Cash & Equivalents stood at $1.3 billion for Q3 2025, which was up 11.45% from $1.2 billion recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Cash & Equivalents peaked at $2.4 billion during Q4 2024, and registered a low of $490.8 million during Q1 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $1.4 billion (2024), whereas its average is $1.6 billion.
  • In the last 5 years, Jazz Pharmaceuticals' Revenue - Interest and Investment Income declined by 10.42% in 2010 and then soared by 44.49% in 2011.
  • Quarterly analysis of 3 years shows Jazz Pharmaceuticals' Revenue - Interest and Investment Income stood at $107.4 million in 2009, then increased by 26.38% to $135.7 million in 2010, then soared by 44.49% to $154.2 million in 2011.
  • Its Cash & Equivalents was $1.3 billion in Q3 2025, compared to $1.2 billion in Q2 2025 and $1.9 billion in Q1 2025.